Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7–17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies
Journal of Child and Adolescent Psychopharmacology · 2024
DOI: 10.1089/cap.2023.0080 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, 2024. Verfasst von Daniel T Radecki und 4 weiteren Autor:innen. Beteiligte Einrichtung: AbbVie, Irvine, California, USA. Hauptthemen laut MEDLINE: Major Depressive Disorder, Milnacipran, Fluoxetine, Delayed-Action Preparations. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Major depressive disorder (MDD) presents a significant psychosocial burden, and there is an unmet need for additional treatment options in pediatric patients. Here, we report the results of two phase 3 multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group studies evaluating the efficacy and safety of levomilnacipran extended release in children and adolescents with MDD.
Methods
In the first study, LVM-MD-11, patients aged 12–17 years received daily doses of levomilnacipran 40 mg ( n = 134), levomilnacipran 80 mg ( n = 138), fluoxetine 20 mg ( n = 134), or placebo ( n = 141). In the second study, LVM-MD-14, patients aged 7–17 years received levomilnacipran 40 to 80 mg ( n = 166), fluoxetine 20 mg ( n = 166), or placebo ( n = 160) daily. Primary and secondary efficacy endpoints were changes in Children's Depression Rating Scale-Revised (CDRS-R) total score and Clinical Global Impressions-Severity (CGI-S) score, respectively.
Results
In LVM-MD-11, there were no significant differences in change in CDRS-R total score between patients treated daily with placebo (least squares mean [LSM] change in CDRS-R total score −22.9) versus levomilnacipran 40 mg (−23.3; p = 0.8035) or 80 mg (−22.6; p = 0.8681). Similarly, in LVM-MD-14, there were no significant differences in LSM change in CDRS-R total score with placebo (−21.3) versus levomilnacipran 40 to 80 mg daily (−23.0; p = 0.2215). There were also no significant differences between the fluoxetine and placebo groups in either study for changes in CDRS-R total score. Changes in CGI-S score were not significant between placebo and levomilnacipran 40 to 80 mg daily or between placebo and fluoxetine. Levomilnacipran was generally well tolerated.
Conclusions
The high placebo response in this study prevented the detection of an effect of levomilnacipran in children and adolescents. Clinical Trial Registration numbers: NCT02431806 and NCT03569475.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AbbVie, Irvine, California, USA.
- AbbVie, North Chicago, Illinois, USA.
- AbbVie, Madison, New Jersey, USA.
- AbbVie, Lake Bluff, Illinois, USA.
- Professional Psychiatric Services, Cincinnati, Ohio, USA.
ORCID-Profile: Mohamed Aziz
Zitieren
APA
Radecki, D. T., Robieson, W. Z., Gopalkrishnan, M., Greenberg, E., & Aziz, M. (2024). Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7–17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2023.0080
Vancouver
Radecki DT, Robieson WZ, Gopalkrishnan M, Greenberg E, Aziz M. Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7–17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies. Journal of Child and Adolescent Psychopharmacology. 2024. doi:10.1089/cap.2023.0080
BibTeX
@article{Radecki2024,
author = {Radecki, Daniel T and Robieson, Weining Z and Gopalkrishnan, Mallika and Greenberg, Edward and Aziz, Mohamed},
title = {Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7–17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies},
journal = {Journal of Child and Adolescent Psychopharmacology},
year = {2024},
doi = {10.1089/cap.2023.0080}
}
EUVIMED